Lead Product(s) : Ervogastat,Clesacostat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The FDA’s decision is informed by the results of Pfizer’s nonclinical studies and a Phase 2a clinical study of PF-06865571 (ervogastat/clesacostat), which showed that treatment with ervogastat/clesacostat reduced liver fat with a favorable safety and...
Product Name : PF-06865571
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Ervogastat,Clesacostat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable